These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
908 related articles for article (PubMed ID: 10955812)
41. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Ioachim E Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860 [TBL] [Abstract][Full Text] [Related]
42. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. Kang WD; Choi HS; Kim SM Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996 [TBL] [Abstract][Full Text] [Related]
43. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Bennett WP; el-Deiry WS; Rush WL; Guinee DG; Freedman AN; Caporaso NE; Welsh JA; Jones RT; Borkowski A; Travis WD; Fleming MV; Trastek V; Pairolero PC; Tazelaar HD; Midthun D; Jett JR; Liotta LA; Harris CC Clin Cancer Res; 1998 Jun; 4(6):1499-506. PubMed ID: 9626468 [TBL] [Abstract][Full Text] [Related]
44. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Gadducci A; Viacava P; Cosio S; Fanelli G; Fanucchi A; Cecchetti D; Cristofani R; Genazzani AR Anticancer Res; 2003; 23(1B):549-56. PubMed ID: 12680144 [TBL] [Abstract][Full Text] [Related]
45. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
46. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719 [TBL] [Abstract][Full Text] [Related]
47. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Kapranos N; Stathopoulos GP; Manolopoulos L; Kokka E; Papadimitriou C; Bibas A; Yiotakis J; Adamopoulos G Anticancer Res; 2001; 21(1B):521-8. PubMed ID: 11299798 [TBL] [Abstract][Full Text] [Related]
48. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220 [TBL] [Abstract][Full Text] [Related]
50. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835 [TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339 [TBL] [Abstract][Full Text] [Related]
52. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992 [TBL] [Abstract][Full Text] [Related]
53. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387 [TBL] [Abstract][Full Text] [Related]
54. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach. Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M; J BUON; 2006; 11(1):31-7. PubMed ID: 17318949 [TBL] [Abstract][Full Text] [Related]
55. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas]. Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068 [TBL] [Abstract][Full Text] [Related]
57. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Bedrosian I; Lee C; Tucker SL; Palla SL; Lu K; Keyomarsi K Clin Cancer Res; 2007 Aug; 13(16):4800-6. PubMed ID: 17699858 [TBL] [Abstract][Full Text] [Related]
58. p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Kwong RA; Kalish LH; Nguyen TV; Kench JG; Bova RJ; Cole IE; Musgrove EA; Sutherland RL Clin Cancer Res; 2005 Jun; 11(11):4107-16. PubMed ID: 15930346 [TBL] [Abstract][Full Text] [Related]
59. Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Green JA; Berns EM; Coens C; van Luijk I; Thompson-Hehir J; van Diest P; Verheijen RH; van de Vijver M; van Dam P; Kenter GG; Tjalma W; Ewing PC; Teodorovic I; Vergote I; van der Burg ME; Eur J Cancer; 2006 Oct; 42(15):2539-48. PubMed ID: 16965910 [TBL] [Abstract][Full Text] [Related]
60. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Anttila MA; Kosma VM; Hongxiu J; Puolakka J; Juhola M; Saarikoski S; Syrjänen K Br J Cancer; 1999 Apr; 79(11-12):1870-8. PubMed ID: 10206307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]